What is the Solara Active Pharma Sciences Ltd share price today?

The share price of NSE:SOLARA-EQ on 07 Sep 2026 (as of 11:00:16 IST) is ₹705.85.

What is the NSE:SOLARA-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:SOLARA-EQ 52 week high low range shows a high of ₹712.00 and a low of ₹422.00.

What is the Solara Active Pharma Sciences Ltd market cap?

As on 07 Sep 2026, Solara Active Pharma Sciences Ltd market cap is ₹3088.03 Cr.

What is the shareholding pattern of Solara Active Pharma Sciences Ltd Stock?

The shareholding pattern of Solara Active Pharma Sciences Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 41.93% Foreign Institutional Investors (FII): 11.52% Domestic Institutional Investors (DII): 2.79% Mutual Funds: 0.95% Retail & Others: 42.81% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Solara Active Pharma Sciences Ltd?

The Price-to-Earnings (PE) ratio of Solara Active Pharma Sciences Ltd is 0, and the Price-to-Book (PB) ratio is 1.52, as on 07 Sep 2026.

Solara Active Pharma Sciences Share Price

727.35+4.45 (+0.62%)

+10.89% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

+0.62%

1 Week

-1.98%

1 Month

+15.72%

3 Month

+28.04%

6 Month

+64.30%

YTD

+28.75%

1 Year

+10.89%

5 Year

-52.40%

10 Year

Max

+197.85%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

715.00

601.20

471.55

422.00

High

752.90

765.00

774.00

About

Solara Active Pharma Sciences is a young dynamic entrepreneurial and customer oriented API manufacturer. The company has a legacy of over three decades and traces its origins to the API Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMANSE

DIVISLABNSE

TORNTPHARMNSE

ZYDUSLIFENSE

CIPLANSE

LAURUSLABSNSE

MANKINDNSE

DRREDDYNSE

AUROPHARMANSE

LUPINNSE

SOLARANSE

LTP

1W Low

1W High

Market cap (₹)

1849.9+12.6 (0.69%)

1832.20

1891.50

4,47,476Cr

9602+227 (2.42%)

9312.50

9740

2,54,764Cr

4928.5+88.5 (1.83%)

4848.50

5010

1,89,423Cr

1180.3+20.3 (1.75%)

1152.10

1190.60

1,16,658Cr

1399+4.5 (0.32%)

1364.50

1419

1,11,484Cr

2026.2+72.2 (3.69%)

1963.80

2055.30

1,09,943Cr

2500+199.3 (8.66%)

2303

2504.30

1,01,712Cr

1200.4+15.4 (1.30%)

1185

1222

1,01,005Cr

1716-18 (-1.04%)

1689.30

1740

99,253Cr

2100.7+17.7 (0.85%)

2080

2135

96,031Cr

727.35-14.7 (-1.98%)

715

765

3,491Cr

Solara Active Pharma Sciences Share Price

727.35+4.45 (+0.62%)

+10.89% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-3%

3 years-2%

Last year7%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year-1472%

Stock Price CAGR

10 years-

5 years-14%

3 years31%

1 year10%

Return on Equity

10 years-2%

5 years-10%

3 years-16%

Last year-1%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-3%	-2%	7%
-	-	-	-1472%
-	-14%	31%	10%
-2%	-10%	-16%	-1%

Peer Comparison

Symbol

SUNPHARMA

DIVISLAB

TORNTPHARM

ZYDUSLIFE

CIPLA

LAURUSLABS

MANKIND

DRREDDY

AUROPHARMA

LUPIN

SOLARA

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,849.9	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,602	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,928.5	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,180.3	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,399	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,026.2	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,500	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,200.4	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,716	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,100.7	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
727.35	₹3491 Cr	—	3.39	20.97	-₹7 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Capital Work in Progress

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Currents Investments

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
—	—	—	—	—	—	—	—	—
₹45 Cr	₹40 Cr	₹36 Cr	₹36 Cr	₹36 Cr	₹36 Cr	₹27 Cr	₹26 Cr	₹25 Cr
₹5 Cr	₹3 Cr	₹2 Cr	₹1 Cr	₹1 Cr	₹4 Cr	₹101 Cr	₹106 Cr	₹0
₹1203 Cr	₹1051 Cr	₹896 Cr	₹1463 Cr	₹1488 Cr	₹1549 Cr	₹958 Cr	₹824 Cr	₹739 Cr
₹1203 Cr	₹1051 Cr	₹896 Cr	₹1463 Cr	₹1488 Cr	₹1549 Cr	₹958 Cr	₹824 Cr	₹739 Cr
₹1253 Cr	₹1094 Cr	₹934 Cr	₹1500 Cr	₹1525 Cr	₹1589 Cr	₹1086 Cr	₹956 Cr	₹764 Cr
₹3 Cr	₹3 Cr	₹3 Cr	₹2 Cr	₹2 Cr	₹4 Cr	₹4 Cr	₹4 Cr	₹4 Cr
₹110 Cr	₹114 Cr	₹106 Cr	₹235 Cr	₹283 Cr	₹155 Cr	₹233 Cr	₹225 Cr	₹243 Cr
₹0	₹0	₹0	-₹79 Cr	-₹55 Cr	-₹26 Cr	₹12 Cr	₹33 Cr	₹48 Cr
₹19 Cr	₹18 Cr	₹12 Cr	₹12 Cr	₹34 Cr	₹41 Cr	₹56 Cr	₹58 Cr	₹25 L
₹53 Cr	₹59 Cr	₹54 Cr	₹49 Cr	₹37 Cr	₹37 Cr	₹33 Cr	₹29 Cr	₹24 Cr
₹183 Cr	₹191 Cr	₹172 Cr	₹217 Cr	₹299 Cr	₹206 Cr	₹333 Cr	₹344 Cr	₹315 Cr
—	—	—	—	—	—	—	—	—
₹274 Cr	₹248 Cr	₹313 Cr	₹306 Cr	₹276 Cr	₹309 Cr	₹216 Cr	₹244 Cr	₹313 Cr
₹105 Cr	₹121 Cr	₹168 Cr	₹144 Cr	₹174 Cr	₹117 Cr	₹157 Cr	₹192 Cr	₹90 Cr
₹501 Cr	₹573 Cr	₹760 Cr	₹649 Cr	₹610 Cr	₹361 Cr	₹354 Cr	₹214 Cr	₹330 Cr
₹14 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹4 Cr	₹2 Cr	₹3 Cr	₹4 Cr	₹5 Cr
₹894 Cr	₹944 Cr	₹1243 Cr	₹1101 Cr	₹1063 Cr	₹789 Cr	₹730 Cr	₹656 Cr	₹738 Cr
₹2333 Cr	₹2232 Cr	₹2351 Cr	₹2821 Cr	₹2890 Cr	₹2588 Cr	₹2153 Cr	₹1960 Cr	₹1821 Cr
₹564 Cr	₹60 Cr	₹60 Cr	₹4 Cr	₹3 Cr	₹6 Cr	₹5 Cr	₹6 Cr	₹8 Cr
₹665 Cr	₹776 Cr	₹999 Cr	₹1001 Cr	₹1025 Cr	₹607 Cr	₹707 Cr	₹538 Cr	₹633 Cr
—	—	—	—	—	—	—	—	—
₹2038 Cr	₹1896 Cr	₹1876 Cr	₹1868 Cr	₹1760 Cr	₹1675 Cr	₹1581 Cr	₹1309 Cr	₹1100 Cr
₹801 Cr	₹705 Cr	₹611 Cr	₹528 Cr	₹429 Cr	₹318 Cr	₹213 Cr	₹121 Cr	₹36 Cr
₹1238 Cr	₹1191 Cr	₹1266 Cr	₹1340 Cr	₹1332 Cr	₹1356 Cr	₹1368 Cr	₹1189 Cr	₹1063 Cr
₹205 Cr	₹280 Cr	₹256 Cr	₹238 Cr	₹239 Cr	₹88 Cr	₹40 Cr	₹40 Cr	₹71 Cr
₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹42 L	₹42 L	₹32 L	₹41 L	₹81 L
₹2 Cr	₹2 Cr	₹2 Cr	₹2 Cr	₹42 L	₹42 L	₹32 L	₹41 L	₹81 L
₹30 Cr	₹28 Cr	₹24 Cr	₹29 Cr	₹55 Cr	₹59 Cr	₹41 Cr	₹36 Cr	₹46 Cr
₹30 L	₹43 L	₹48 L	₹51 L	₹48 L	₹1 Cr	₹3 Cr	₹17 Cr	₹9 Cr
₹1474 Cr	₹1503 Cr	₹1550 Cr	₹1633 Cr	₹1651 Cr	₹1530 Cr	₹1481 Cr	₹1312 Cr	₹1214 Cr
—	—	—	—	—	—	—	—	—
₹3 Cr	₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹0
₹318 Cr	₹318 Cr	₹360 Cr	₹558 Cr	₹576 Cr	₹295 Cr	₹280 Cr	₹214 Cr	₹188 Cr
₹439 Cr	₹327 Cr	₹349 Cr	₹537 Cr	₹490 Cr	₹484 Cr	₹227 Cr	₹289 Cr	₹263 Cr
₹50 Cr	₹4 Cr	₹9 Cr	₹9 Cr	₹47 Cr	₹199 Cr	₹57 Cr	₹76 Cr	₹47 Cr
₹20 Cr	₹29 Cr	₹19 Cr	₹23 Cr	₹18 Cr	₹73 Cr	₹40 Cr	₹49 Cr	₹75 Cr
₹29 Cr	₹52 Cr	₹52 Cr	₹60 Cr	₹109 Cr	₹7 Cr	₹69 Cr	₹20 Cr	₹35 Cr
₹858 Cr	₹729 Cr	₹788 Cr	₹1188 Cr	₹1239 Cr	₹1058 Cr	₹672 Cr	₹648 Cr	₹608 Cr
-₹36 Cr	-₹215 Cr	-₹455 Cr	₹86 Cr	₹176 Cr	₹269 Cr	-₹58 Cr	-₹7 Cr	-₹130 Cr
₹2333 Cr	₹2232 Cr	₹2351 Cr	₹2821 Cr	₹2890 Cr	₹2588 Cr	₹2153 Cr	₹1960 Cr	₹1821 Cr
₹280	₹271	₹259	₹416	₹423	₹441	₹367	₹330	₹310
₹280	₹271	₹239	₹384	₹390	₹407	₹338	₹330	₹310

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Cash & Cash Equivalent on Amalgamation / Take over / Merger

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020	Mar 2019	Mar 2018
-₹7 Cr	₹54 L	-₹488 Cr	-₹45 Cr	-₹91 Cr	₹222 Cr	₹115 Cr	₹58 Cr	₹20 L
₹201 Cr	₹210 Cr	₹406 Cr	₹187 Cr	₹181 Cr	₹173 Cr	₹168 Cr	₹148 Cr	₹63 Cr
-₹38 Cr	₹3 Cr	₹191 Cr	₹74 L	-₹314 Cr	-₹206 Cr	-₹16 Cr	-₹25 Cr	-₹11 Cr
₹155 Cr	₹214 Cr	₹108 Cr	₹143 Cr	-₹224 Cr	₹189 Cr	₹266 Cr	₹181 Cr	₹52 Cr
₹153 Cr	₹213 Cr	₹109 Cr	₹156 Cr	-₹242 Cr	₹155 Cr	₹242 Cr	₹166 Cr	₹49 Cr
-₹99 Cr	-₹37 Cr	-₹4 Cr	-₹81 Cr	-₹243 Cr	-₹106 Cr	-₹359 Cr	-₹116 Cr	-₹85 Cr
-₹54 Cr	-₹180 Cr	-₹106 Cr	-₹113 Cr	₹334 Cr	₹92 Cr	₹97 Cr	-₹23 Cr	₹68 Cr
₹53 L	-₹4 Cr	-₹29 L	-₹38 Cr	-₹151 Cr	₹142 Cr	-₹20 Cr	₹27 Cr	₹31 Cr
₹4 Cr	₹8 Cr	₹9 Cr	₹46 Cr	₹198 Cr	₹56 Cr	₹76 Cr	₹46 Cr	₹0
₹0	₹0	₹0	₹0	₹0	₹0	₹0	₹3 Cr	₹14 Cr
₹4 Cr	₹4 Cr	₹8 Cr	₹9 Cr	₹46 Cr	₹198 Cr	₹56 Cr	₹76 Cr	₹46 Cr

Fundamental Ratios

Consolidated

Standalone

Solara Active Pharma Sciences Share Price

727.35+4.45 (+0.62%)

+10.89% past 1 Year

Shareholding summary

Promoters

41.93%

FII

11.52%

DII

2.79%

0.95%

Others

42.81%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
41.93%	42.00%	42.00%	42.01%	42.01%	37.94%
11.52%	11.59%	11.98%	13.58%	14.25%	14.63%
2.79%	2.57%	2.46%	1.51%	1.44%	1.33%
0.95%	1.18%	1.18%	1.18%	1.18%	1.28%
42.81%	42.66%	42.38%	41.72%	41.12%	44.82%

Bulk & block deals

Name

Junomoneta Finsol Private Limited

Tpg Growth Iv Sf Pte Ltd

Fssa Indian Subcontinent Fund

Pronomz Ventures Llp

Spiracca Ventures Llp

Pronomz Ventures Llp

Spiracca Ventures Llp

Aarti Bhatia

Bhatia Suresh

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
20 Aug 2026	Purchase	17.75 Cr	₹626.19	2.83 L	Bulk	0.589746	NSE
20 Aug 2026	Sell	17.71 Cr	₹626.82	2.83 L	Bulk	0.587858	NSE
10 Jul 2026	Sell	17.20 Cr	₹573.20	3 L	Bulk	0.624246	NSE
20 Jun 2025	Sell	12.09 Cr	₹538.11	2.25 L	Bulk	0.467622	NSE
16 Jun 2025	Purchase	99 Cr	₹495	20 L	Bulk	4.161638	NSE
16 Jun 2025	Sell	99 Cr	₹495	20 L	Bulk	4.161638	NSE
16 Jun 2025	Purchase	99 Cr	₹495	20 L	Block	4.161638	NSE
16 Jun 2025	Sell	99 Cr	₹495	20 L	Block	4.161638	NSE
24 Feb 2025	Purchase	10.02 Cr	₹490	2.05 L	Bulk	0.425584	BSE
24 Feb 2025	Sell	10.02 Cr	₹490	2.05 L	Bulk	0.425584	BSE

Insider trading & SAST

Client name

Mitsubishi Ufj Financial Group (Mufg)

Pronomz Ventures Llp

Poorvank Purohit

Vishal Mathur

Pronomz Ventures Llp

Sandeep Shashikantha Rao

Kausalya Santhanam

Pronomz Ventures Llp

Pronomz Ventures Llp (Revised)

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
14 Oct 2025	Other	Disposal	2.16	4.37	0	—	9.64 L	01 Sep 2025	Indirect Sale	19,47,923	SAST	29(2)	—
12 Jul 2025	Promoter	Acquisition	4.16	42.1	0	—	20 L	16 Jun 2025	Market	2,02,31,281	SAST	29(2)	—
01 Jul 2025	Other	Disposal	0.022604	0.28	63.19 L	₹631.88	10 K	30 Jun 2025	Market Sale	1,34,177	Insider Trading	—	Equity Shares
01 Jul 2025	Other	Disposal	0.010902	0.3	29.55 L	₹612.68	4.82 K	25 Jun 2025	Market Sale	1,44,177	Insider Trading	—	Equity Shares
27 Jun 2025	Employee	Acquisition	0.012371	0.04	29.79 L	₹544.30	5.47 K	23 Jun 2025 - 24 Jun 2025	Market Purchase	17,916	Insider Trading	—	Equity Shares
19 Jun 2025	Promoter	Acquisition	4.520775	9.71	99 Cr	₹495	20 L	16 Jun 2025	Market Purchase	46,74,424	Insider Trading	—	Equity Shares
09 Jun 2025	Director	Acquisition	0.00226	0	4.74 L	₹473.99	1 K	04 Jun 2025	Market Purchase	1,000	Insider Trading	—	Equity Shares
14 Mar 2025	Director	Acquisition	0.002484	0.01	5 L	₹500.06	1 K	11 Mar 2025	Market Purchase	1,876	Insider Trading	—	Equity Shares
06 Mar 2025	Promoter	Acquisition	0.033786	5.57	62.76 L	₹461.50	13.60 K	28 Feb 2025	Market Purchase	26,74,424	Insider Trading	—	Equity Shares
04 Mar 2025	Promoter	Acquisition	0.537492	5.54	10.26 Cr	₹474.31	2.16 L	21 Feb 2025 - 24 Feb 2025	Market Purchase	26,60,824	Insider Trading	—	Equity Shares

Solara Active Pharma Sciences Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Solara Active Pharma Sciences Share Price

Solara Active Pharma Sciences Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Solara Active Pharma Sciences Share Price

Solara Active Pharma Sciences Share Price

Oscillators

Moving averages

Solara Active Pharma Sciences Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Solara Active Pharma Sciences Share Price

Corporate Actions

Company details

Solara Active Pharma Sciences Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Solara Active Pharma Sciences Share Price

News

Solara Active Pharma tax demand of Rs 161.92 crores fully withdrawn

Solara Active Pharma plans Rs 55-60 crores capex in FY27 for expansion

Solara Active Pharma Sciences Q1 EBITDA rises YoY, margin moderates slightly

Solara Active Pharma Sciences reports strong Q1 revenue growth on YoY basis

Solara Active Pharma Sciences reports strong YoY growth in Q1 net profit

Solara Active Pharma Sciences to host Q1 FY26 earnings conference call

Solara Active Pharma Sciences posts strong Q4 FY26 growth with record margins

Solara Active Pharma Sciences reports higher Q4 revenue on annual basis

Solara Active Pharma Sciences Q4 EBITDA rises YoY but margins contract

Solara Active Pharma Q4 swings to profit from loss on year-on-year basis

Solara Active Pharma Receives US FDA EIR for Puducherry Facility, Inspection Classified as VAI.

Solara Active Pharma Sciences approves Rs 112.50 final call on partly-paid rights shares, record date April 2, 2026.

Solara Active Pharma Sciences Faces Rs 161.92 Cr Tax Demand for AY20 from Thane Authority

Solara Active Pharma Sciences Reports Q3 Revenue Growth but Net Loss Against Prior Profit.

Solara Active Pharma Sciences Q3FY26 EBITDA Declines 35% YoY to Rs 37.40 Crores.

Solara Active Pharma Sciences Reports Q3 FY26 Consolidated Net Loss of Rs 17.40 Crores Vs YoY Profit.

Solara Active Pharma Sciences appoints Mohanraj S as executive director

Solara Active Pharma Sciences Q2 FY26 net loss, revenue and margins decline on YoY basis.

Solara Active Pharma Sciences: Q1 Ebitda 57.00 Crores Rupees Vs 41.90 Crores (Yoy) || Q1 Ebitda Margin 17.87% Vs 11.5% (Yoy)

Solara Active Pharma Sciences: Q1 Cons Net Profit 10.50 Crores Rupees Vs Loss 13.50 Crores (Yoy) || Q1 Revenue 320.00 Crores Rupees Vs 363.00 Crores (Yoy)

Solara Active Pharma Sciences Ltd Share Price Today

Solara Active Pharma Sciences Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator